Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel

Jeong Cheon Ahn, Woo Hyuk Song, Jung Ah Kwon, Chang Gyu Park, Hong Seok Seo, Dong Joo Oh, Young Moo Rho

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


Background: A recent study has shown that triple anti-platelet therapy (cilostazol+clopidogrel+aspirin) resulted in a significantly lower restenosis rate after coronary stenting than did conventional therapy (clopidogrel+aspirin) . However, the anti-platelet effects of cilostazol, when combined with clopidogrel and aspirin, have not been evaluated. Methods: Low dose cilostazol (50 mg/BID) was given to 47 patients who had already been taking clopidogrel (75 mg/day) and aspirin (100 mg/day) for more than 1 month subsequent to coronary stenting due to AMI and unstable angina. Markers of platelet activation, P-selectin and activated GPIIb/IIIa on platelets, were measured at baseline and 2 weeks after cilostazol treatment. We empirically divided patients into tertiles (low, n=16; moderate, n=14; high group, n=17), according to the baseline P-selectin expression. We then performed a comparative assessment of the anti-platelet effects of cilostazol at baseline and after 2 weeks of cilosatzol administration. Results: P-selectin was significantly decreased after 2 weeks of cilostazol treatment in total patients (n=47, 3.2± 2.4% to 2.0±1.9%, p=0.03). This inhibition of P-selectin expression was mainly achieved in the moderate and high P-selectin groups (low group; 1.4±0.5 to 1.9±1.3%, p>0.05, moderate group; 2.5±0.3 to 1.3±0.3%, p<0.05, high group; 5.4±2.7 to 2.7±2.8%, p<0.05). Activated GPIIb/IIIa was not significantly changed (13.5% to 17.6%, p>0.05). Underlying disease, cardiovascular risk factors, concomitant medication including statin, and hsCRP were not related to the degree of P-selectin expression. Conclusion: Our data demonstrated that cilostazol treatment in addition to conventional anti-platelet therapy provides more effective suppression of platelet P-selectin expression in patients with relatively high platelet activity.

Original languageEnglish
Pages (from-to)230-236
Number of pages7
JournalKorean Journal of Internal Medicine
Issue number4
Publication statusPublished - 2004 Dec
Externally publishedYes


  • Antiplatelet therapy
  • Coronary stent

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel'. Together they form a unique fingerprint.

Cite this